$13M More For Lung Cancer Research Funding
House Passes Department of Defense (DOD) Appropriations Bill
Jun 11, 2015, 05:50 ET
WASHINGTON, June 11, 2015 /PRNewswire-USNewswire/ -- Today, the House of Representatives passed the FY16 Department of Defense (DOD) Appropriations Bill. This legislation includes $13 million for lung cancer research under the Congressionally Directed Medical Research Program (CDMRP) bringing the total funding to $102M.
This effort comes on the heels of the passage of an amendment, offered by Congressman Rick Nolan (D-MN), that provides an additional $1 million to the DOD Lung Cancer Research Program (LCRP). In 2008, Lung Cancer Alliance worked to help establish this dedicated research funding pipeline.
"As a Minnesotan, I am thrilled that Congressman Nolan has put his stamp on this issue," said Shelly Engfer-Triebenbach, lung cancer survivor and Lung Cancer Alliance advocate. "His support means everything to our community that is far too often ignored by Washington decision-makers. His actions show that he truly understands our needs and is watching out for us, and for that, we are very grateful."
The Senate still has FY16 DOD funding under consideration. Details of the CDMRP can be viewed here: http://cdmrp.army.mil/lcrp/default.shtml.
About Lung Cancer Alliance:
Lung Cancer Alliance (LCA), www.lungcanceralliance.org, is committed to saving lives and accelerating research by empowering people living with or at risk for lung cancer. LCA provides live, professional support, referral and information services to patients, their loved ones and those at risk for lung cancer; conducts national awareness campaigns including the award winning No One Deserves to Die Campaign attacking the stigma of the disease and the Moments Campaign spreading word about the risk and screening with a risk navigator tool for consumers; and advocates for multiple millions in public health dollars for lung cancer research. LCA has earned a prestigious four star rating from Charity Navigator.
Media Contact: Chris Davis
SOURCE Lung Cancer Alliance
Share this article